Xeraya Capital
VC Fund
Kuala Lumpur, Malaysia
Xeraya Capital is a private equity and venture capital firm.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 29%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Xeraya Capital invests in
BiotechnologyHealth CareTherapeuticsMedical DeviceManufacturing
Stages Xeraya Capital invests in
Series BSeries CVenture - Series UnknownSeries ASeries D
Countries Xeraya Capital invests in
United StatesIsraelGermanySingaporeUnited Kingdom
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bruce Cohen
|
|||
|
Fares Zahir
|
|||
James Tee
|
|||
Jason Rushton
|
|||
Investment Focus
Industry
- Biotechnology 14 (58%)
- Health Care 7 (29%)
- Therapeutics 7 (29%)
- Medical Device 5 (21%)
- Manufacturing 4 (17%)
Stage
- Series B 6 (25%)
- Series C 6 (25%)
- Venture - Series Unknown 3 (13%)
- Series A 2 (8%)
- Series D 2 (8%)
Country
- United States 14 (58%)
- Israel 1 (4%)
- Germany 1 (4%)
- Singapore 1 (4%)
- United Kingdom 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bruce Cohen
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Fares Zahir
CEO & Co-Founder
|
CEO & Co-Founder | Total investments: 1 | Find email | |
|
James Tee
Vice President - Investments
|
Vice President - Investments | Total investments: 0 | Find email | |
|
Jason Rushton
Investments Partner
|
Investments Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection andsupport the health of bees and other pollinators. | $125.5M / Post-IPO Equity / Feb 03, 2022 | ||
| OncoMyx Therapeutics develops oncolytic immunotherapies called myxoma (MYXV) to assist in creating an immune response and treat cancer. Its myxoma virus (MYXV) platform targets hematologic and solid tumors with a unique oncolytic virus called myxoma and a novel patented systemic delivery approach which can be carried systemically by humanleukocytes where it can then infect tumor cells.The company was founded in 2018 and is headquartered in Phoenix, Arizona. | $50M / Series B / Dec 09, 2021 | ||
| OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. The company's MYXV platform, is poised to be a best-in-class OV approach. The company assembled the top OV team around MYXV to advance a pipeline of oncology therapeutics for the benefit ofcancer patients. | $50M / Series B / Dec 08, 2021 | ||
| Imago BioSciences is a clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financial commitment of its investors tofocus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.Imago BioSciences was founded in 2012 and is based in Redwood City, California. | $80M / Series C / Nov 19, 2020 | ||
| InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum orplasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.It was founded in 2017 and headquartered in Redwood City, California. | $34M / Series B / Nov 16, 2020 | ||
| Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of geneticdisease for patients.It was founded in 2013 and headquartered in Cambridge, Cambridgeshire. | $50M / Series C / Nov 09, 2020 | ||
| Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $120M / Private Equity / May 20, 2020 | ||
| GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection andsupport the health of bees and other pollinators. | $17M / Venture - Series Unknown / May 12, 2020 | ||
| Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart. | $31M / Series B / Feb 25, 2020 | ||
| P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | $12M / Series C / Jan 29, 2020 | ||
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
48,627 investors
Climate Investors
45,169 investors
Manufacturing Investors
27,682 investors
Biotech Investors
24,131 investors
Biotechnology Investors
21,397 investors
Medical Device Investors
12,432 investors
Health Care VC Funds
36,465 investors
Climate VC Funds
37,034 investors
Manufacturing VC Funds
24,165 investors
FAQ
What does Xeraya Capital invest in?
Xeraya Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Xeraya Capital?
Public channels for Xeraya Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Xeraya Capital?
The team at Xeraya Capital includes Bruce Cohen (Venture Partner), Fares Zahir (CEO & Co-Founder) and James Tee (Vice President - Investments). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
